Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Perspective
Nature Reviews Cancer 2, 787–794 (1 October 2002) | doi:10.1038/nrc908
Anti-oestrogenic prevention of breast cancer — the make or break point
Abstract
Clinical trials have shown that giving anti-oestrogens to healthy women can reduce the early incidence of breast cancer by |[sim]|40%. However, the large numbers of women treated, compared with the few who get breast cancer, together with the not insignificant toxicity and the unknown long-term clinical benefits and risks, makes this strategy of prevention versus treatment precarious. So how can we improve the odds for the successful use of endocrine chemoprevention?
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
